JP6004494B2 - デュピュイトラン病の治療 - Google Patents

デュピュイトラン病の治療 Download PDF

Info

Publication number
JP6004494B2
JP6004494B2 JP2013535462A JP2013535462A JP6004494B2 JP 6004494 B2 JP6004494 B2 JP 6004494B2 JP 2013535462 A JP2013535462 A JP 2013535462A JP 2013535462 A JP2013535462 A JP 2013535462A JP 6004494 B2 JP6004494 B2 JP 6004494B2
Authority
JP
Japan
Prior art keywords
tnf
disease
antagonist
dupuytren
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013535462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540803A (ja
JP2013540803A5 (enExample
Inventor
ナンチャハル，ジャグディープ
スザンヌ ミッドウッド，キム
スザンヌ ミッドウッド，キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1018325.9A external-priority patent/GB201018325D0/en
Priority claimed from GBGB1018362.2A external-priority patent/GB201018362D0/en
Priority claimed from GBGB1113718.9A external-priority patent/GB201113718D0/en
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of JP2013540803A publication Critical patent/JP2013540803A/ja
Publication of JP2013540803A5 publication Critical patent/JP2013540803A5/ja
Application granted granted Critical
Publication of JP6004494B2 publication Critical patent/JP6004494B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2013535462A 2010-10-30 2011-10-31 デュピュイトラン病の治療 Active JP6004494B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1018325.9A GB201018325D0 (en) 2010-10-30 2010-10-30 Treatment for dupuytren's disease
GB1018325.9 2010-10-30
GBGB1018362.2A GB201018362D0 (en) 2010-11-01 2010-11-01 Treatment of dupuytren's disease
GB1018362.2 2010-11-01
GB1113718.9 2011-08-10
GBGB1113718.9A GB201113718D0 (en) 2011-08-10 2011-08-10 Treatment of Dupuytren's Disease
PCT/EP2011/069147 WO2012056044A1 (en) 2010-10-30 2011-10-31 Treatment for dupuytren's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016166524A Division JP2017014266A (ja) 2010-10-30 2016-08-29 デュピュイトラン病の治療

Publications (3)

Publication Number Publication Date
JP2013540803A JP2013540803A (ja) 2013-11-07
JP2013540803A5 JP2013540803A5 (enExample) 2014-12-18
JP6004494B2 true JP6004494B2 (ja) 2016-10-12

Family

ID=44913268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013535462A Active JP6004494B2 (ja) 2010-10-30 2011-10-31 デュピュイトラン病の治療
JP2016166524A Pending JP2017014266A (ja) 2010-10-30 2016-08-29 デュピュイトラン病の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016166524A Pending JP2017014266A (ja) 2010-10-30 2016-08-29 デュピュイトラン病の治療

Country Status (9)

Country Link
US (3) US9138458B2 (enExample)
EP (1) EP2632446B1 (enExample)
JP (2) JP6004494B2 (enExample)
AU (2) AU2011322482B2 (enExample)
CA (1) CA2847197C (enExample)
DK (1) DK2632446T3 (enExample)
ES (1) ES2715204T3 (enExample)
RU (1) RU2013123796A (enExample)
WO (1) WO2012056044A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2715204T3 (es) 2010-10-30 2019-06-03 Univ Oxford Innovation Ltd Tratamiento de la enfermedad de Dupuytren
CA2872227A1 (en) 2012-05-01 2013-11-07 Proteolease Ltd. Methods for extracting a tooth
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
EP3019017A4 (en) * 2013-07-11 2017-09-27 180 Therapeutics LP Method of treating fibroproliferative disorders including dupuytren ' s disease with one or more specific human matrix metalloproteinase and a tnf antagonist
HK1247622A1 (zh) * 2015-03-02 2018-09-28 180 Therapeutics Lp 利用il-33拮抗剂来治疗局部纤维化的方法
EP3439701A4 (en) * 2016-04-08 2019-12-11 180 Therapeutics LP METHOD FOR THE TREATMENT OF DUPUYTRIAL DISEASE IN EARLY STAGE
WO2018045213A1 (en) * 2016-09-02 2018-03-08 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
EP3570865A4 (en) * 2016-09-02 2020-05-20 180 Therapeutics LP METHOD FOR TREATING A LOCALIZED FIBROTIC DISEASE USING A BISPECIFIC IL-33 / TNF ANTIBODY
US11564963B2 (en) 2017-11-22 2023-01-31 Progeneron, Llc Topical compositions, process of large-scale manufacture, and method of use
EP3980022B1 (en) 2019-06-07 2025-01-15 Dale Biotech, LLC Treatment of dupuytren's disease, osteoarthritis, or adhesive capsulitis with rhamnolipids.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
US6486140B2 (en) * 1994-07-19 2002-11-26 Medicarb Ab Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1083337C (zh) 1996-03-26 2002-04-24 精工爱普生株式会社 打印装置及其控制方法
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
GB0105330D0 (en) 2001-03-02 2001-04-18 Renovo Ltd Genetic testing
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2002087576A1 (en) * 2001-04-30 2002-11-07 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
DE60327075D1 (de) 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
GB0306165D0 (en) 2003-03-18 2003-04-23 Delta G Ltd Medical treatment
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US20050186261A1 (en) * 2004-01-30 2005-08-25 Angiotech International Ag Compositions and methods for treating contracture
CA2593038C (en) * 2005-01-21 2015-03-17 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
EP2403353B1 (en) 2009-03-06 2019-08-14 Kenneth William Gregg Composition for controlling fish
US20110229451A2 (en) 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
ES2715204T3 (es) * 2010-10-30 2019-06-03 Univ Oxford Innovation Ltd Tratamiento de la enfermedad de Dupuytren

Also Published As

Publication number Publication date
EP2632446A1 (en) 2013-09-04
US9138458B2 (en) 2015-09-22
CA2847197C (en) 2020-11-03
AU2011322482B2 (en) 2017-03-23
JP2013540803A (ja) 2013-11-07
DK2632446T3 (en) 2019-04-01
RU2013123796A (ru) 2014-12-10
US20160280775A1 (en) 2016-09-29
US20190322733A1 (en) 2019-10-24
US20130287760A1 (en) 2013-10-31
US10669334B2 (en) 2020-06-02
US10273296B2 (en) 2019-04-30
CA2847197A1 (en) 2012-05-03
JP2017014266A (ja) 2017-01-19
EP2632446B1 (en) 2018-12-12
AU2017204267A1 (en) 2017-07-13
AU2017204267B2 (en) 2019-05-23
AU2011322482A1 (en) 2013-05-23
WO2012056044A1 (en) 2012-05-03
ES2715204T3 (es) 2019-06-03

Similar Documents

Publication Publication Date Title
JP2017014266A (ja) デュピュイトラン病の治療
JP7212653B2 (ja) 抗炎症剤としてのｐｒｇ４の使用
Qian et al. Downregulating PI3K/Akt/NF-κB signaling with allicin for ameliorating the progression of osteoarthritis: in vitro and vivo studies
Foster et al. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study
US20150246966A1 (en) Therapeutic Compositions for the Treatment of Dry Eye Disease
JP5646617B2 (ja) 多発性硬化症の治療のための組成物および方法
US20060276385A1 (en) Anti-inflammatory agents and methods of their use
AU2017248273B2 (en) Method of treating early stage Dupuytren's disease
WO2013064585A1 (en) Treatment of musculoskeletal fibroproliferative disorders
CN119546340A (zh) 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法
Nanchahal et al. Treatment for dupuytren's disease
US11980635B2 (en) Methods of oral administration of protocatechuic acid for treating or reducing the severity of a joint injury or disease
WO2014023952A2 (en) Prevention and treatment of osteoarthritis
US12221463B2 (en) Method of promoting wound healing by inhibiting CCR3
CN121003696A (zh) 一种靶向b细胞和软骨细胞衰老的骨关节炎治疗药物
US20230355648A1 (en) Biological total joint replacement
KR20180035911A (ko) Fgf-18 화합물을 포함하는 조합 조성물
CN120882750A (zh) 含有icam-1抑制剂的纤维化治疗剂
CN117379403A (zh) 降低pdi活性的物质在治疗自身免疫性疾病产品中的应用
Andersone et al. Oxidant—antioxidant system in patients with reactive arthritis
Wang et al. 1251: Wogonin Suppresses Cellular Proliferation and Expression of Monocyte Chemoattractant Protein 1 in Peyronie's Plaque-Derived Cells
Asgarian Anti-Inflammatory Therapeutic Approaches to Prevent or Delay Post-Traumatic Osteoarthritis (PTOA) of the Knee Joint with a Focus on Sustained Delivery Approaches

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160901

R150 Certificate of patent or registration of utility model

Ref document number: 6004494

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S633 Written request for registration of reclamation of name

Free format text: JAPANESE INTERMEDIATE CODE: R313633

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250